Phase 2 trial of somapacitan demonstrate potential as an efficacious once─weekly treatment for childhood growth hormone deficiency

Somapacitan, a novel growth hormone derivative in development for once─weekly administration of growth hormone, matched the therapeutic benefits of once─daily Norditropin (somatropin) in a phase 2 trial in

More From BioPortfolio on "Phase 2 trial of somapacitan demonstrate potential as an efficacious once─weekly treatment for childhood growth hormone deficiency"